Prospective Grant of an Exclusive Patent License: Methods of Modulating Erythropoiesis With Arginine Vasopressin Receptor 1B Molecules, 29127 [2018-13443]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13419 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Methods of Modulating
Erythropoiesis With Arginine
Vasopressin Receptor 1B Molecules
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Dental and Craniofacial Research, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patent Applications listed in the
Supplementary Information section of
this notice to ERYTHRYx Therapeutics,
located in Los Angeles, California.
DATES: Only written comments and/or
applications for a license which are
received by the Office of Technology
Transfer and Innovation Access,
National Institute of Dental and
Craniofacial Research on or before July
9, 2018 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Yun Mei, Technology
Transfer and Patent Specialist, Office of
Technology Transfer and Innovation
Access, National Institute of Dental and
Craniofacial Research, National
Institutes of Health, BLDG 1 DEM,
RM667, 6701 Democracy Blvd.,
Bethesda, MD 20817; Telephone: (301)
827–4639; Facsimile: (301) 496–1005;
Email: yun.mei@nih.gov.
SUPPLEMENTARY INFORMATION:
daltland on DSKBBV9HB2PROD with NOTICES
SUMMARY:
Intellectual Property
1. U.S. Provisional Patent Application
No. 61/885,258, filed October 1, 2013
and entitled ‘‘Methods of Modulating
Erythropoiesis with Arginine
Vasopressin Receptor 1B Molecules’’
VerDate Sep<11>2014
17:16 Jun 21, 2018
Jkt 244001
(HHS Reference No. E–619–2013–0–US–
01);
2. PCT Application No. PCT/US2014/
058613, filed October 1, 2014 and
entitled ‘‘Methods of Modulating
Erythropoiesis with Arginine
Vasopressin Receptor 1B Molecules’’
(HHS Reference No. E–619–2013–0–
PCT–02);
3. U.S. Patent Application No. 15/
022,531, filed March 16, 2016 and
entitled ‘‘Methods of Modulating
Erythropoiesis with Arginine
Vasopressin Receptor 1B Molecules’’
(HHS Reference No. E–619–2013–0–US–
03);
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be the United States and
the field of use may be limited to ‘‘Use
of arginine vasopressin receptor 1B
agonists to treat anemia caused by (i)
chronic renal failure on dialysis, (ii)
receiving myelosuppressive
chemotherapy, or (iii) lacking
antidiuretic hormone.’’
The subject technology is a method of
using arginine vasopressin receptor 1B
(AVPR1B) agonists to increase the
number of red blood cells to treat
anemia. The inventors discovered that
hematopoietic stem cells express
AVPR1B receptor, and these receptors
play a key role in promoting
hematopoietic stem and progenitor cell
proliferation. The number of red blood
cells and their precursors significantly
increased on day 2 following
vasopressin administration, an onset
time much faster than erythropoietin
(EPO), which is commonly used to
stimulate red blood cell production for
anemia treatment. EPO takes about a
week to manifest its clinical effects. The
AVPR1B agonists can be used to
jumpstart the hematopoietic system and
erythropoietin can be used to sustain
the effect.
The subject technology is a
repurposing of an existing drug,
vasopressin, an AVPR1B agonist, also
called antidiuretic hormone. It is a nineamino acid peptide secreted from the
posterior pituitary and used to treat
patients with central diabetes insipidus,
an uncommon disorder that causes an
imbalance of water in the body. This
imbalance leads to excretion of large
amount of urine (polyuria) and intense
thirst even after drinking fluids
(polydipsia).
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
29127
within fifteen (15) days from the date of
this published notice, the National
Institute of Dental and Craniofacial
Research receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: June 19, 2018.
David W. Bradley,
Director, Office of Technology Transfer and
Innovation Access, National Institute of
Dental and Craniofacial Research, National
Institutes of Health.
[FR Doc. 2018–13443 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Barry Buchbinder, 240–627–3678;
barry.buchbinder@nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
SUMMARY:
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 83, Number 121 (Friday, June 22, 2018)]
[Notices]
[Page 29127]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13443]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Methods of
Modulating Erythropoiesis With Arginine Vasopressin Receptor 1B
Molecules
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Dental and Craniofacial Research, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an Exclusive Patent
License to practice the inventions embodied in the Patent Applications
listed in the Supplementary Information section of this notice to
ERYTHRYx Therapeutics, located in Los Angeles, California.
DATES: Only written comments and/or applications for a license which
are received by the Office of Technology Transfer and Innovation
Access, National Institute of Dental and Craniofacial Research on or
before July 9, 2018 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Yun Mei, Technology Transfer and Patent
Specialist, Office of Technology Transfer and Innovation Access,
National Institute of Dental and Craniofacial Research, National
Institutes of Health, BLDG 1 DEM, RM667, 6701 Democracy Blvd.,
Bethesda, MD 20817; Telephone: (301) 827-4639; Facsimile: (301) 496-
1005; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. U.S. Provisional Patent Application No. 61/885,258, filed
October 1, 2013 and entitled ``Methods of Modulating Erythropoiesis
with Arginine Vasopressin Receptor 1B Molecules'' (HHS Reference No. E-
619-2013-0-US-01);
2. PCT Application No. PCT/US2014/058613, filed October 1, 2014 and
entitled ``Methods of Modulating Erythropoiesis with Arginine
Vasopressin Receptor 1B Molecules'' (HHS Reference No. E-619-2013-0-
PCT-02);
3. U.S. Patent Application No. 15/022,531, filed March 16, 2016 and
entitled ``Methods of Modulating Erythropoiesis with Arginine
Vasopressin Receptor 1B Molecules'' (HHS Reference No. E-619-2013-0-US-
03);
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be the United
States and the field of use may be limited to ``Use of arginine
vasopressin receptor 1B agonists to treat anemia caused by (i) chronic
renal failure on dialysis, (ii) receiving myelosuppressive
chemotherapy, or (iii) lacking antidiuretic hormone.''
The subject technology is a method of using arginine vasopressin
receptor 1B (AVPR1B) agonists to increase the number of red blood cells
to treat anemia. The inventors discovered that hematopoietic stem cells
express AVPR1B receptor, and these receptors play a key role in
promoting hematopoietic stem and progenitor cell proliferation. The
number of red blood cells and their precursors significantly increased
on day 2 following vasopressin administration, an onset time much
faster than erythropoietin (EPO), which is commonly used to stimulate
red blood cell production for anemia treatment. EPO takes about a week
to manifest its clinical effects. The AVPR1B agonists can be used to
jumpstart the hematopoietic system and erythropoietin can be used to
sustain the effect.
The subject technology is a repurposing of an existing drug,
vasopressin, an AVPR1B agonist, also called antidiuretic hormone. It is
a nine-amino acid peptide secreted from the posterior pituitary and
used to treat patients with central diabetes insipidus, an uncommon
disorder that causes an imbalance of water in the body. This imbalance
leads to excretion of large amount of urine (polyuria) and intense
thirst even after drinking fluids (polydipsia).
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Institute of Dental and Craniofacial Research receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: June 19, 2018.
David W. Bradley,
Director, Office of Technology Transfer and Innovation Access, National
Institute of Dental and Craniofacial Research, National Institutes of
Health.
[FR Doc. 2018-13443 Filed 6-21-18; 8:45 am]
BILLING CODE 4140-01-P
